U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07857733) titled 'Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1' on Sept. 24.

Brief Summary: A Phase 3 open-label extension study of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Complex Regional Pain Syndrome Type I

Intervention: DRUG: Neridronate

100 mg, given as a 2-hour infusion on Days 1, 4, 7, and 10.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ambros Therapeutics, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....